
HARROW, INC.
99
Recent news highlights Harrow's Q3 2026 earnings report showing revenue and earnings challenges, ongoing pipeline progress, and commercial activities including product launches and acquisitions.
- Harrow reported Q3 2026 earnings with revenue and earnings below expectations, continuing a trend of quarterly losses and revenue misses in 2026 [N1][N2].
- The company is advancing MELT-300 toward FDA approval following completion of Phase 3 trials and ongoing supporting studies [N1].
- Harrow completed acquisition of TYRVAYA nasal spray for dry eye disease in October 2026, with ongoing licensing discussions related to VEVYE restrictions [N1].
- Sales and marketing efforts continue to focus on expanding U.S. market penetration with recent product launches including BYOOVIZ and BYQLOVI in mid-2026 [N1][N4].
- The company reported net income of $9.76 million and maintained strong liquidity with $75.3 million cash and equivalents as of September 30, 2026 [S2].
Harrow, Inc. specializes in ophthalmic disease management solutions, offering a portfolio of FDA-approved branded pharmaceuticals and compounded medications primarily in the U.S. market. Its products address a range of eye conditions including dry eye disease, wet AMD, cataracts, and ocular surface diseases. The company operates two compounding facilities in New Jersey and outsources manufacturing of branded products to third parties across multiple countries. Harrow's pipeline includes late-stage candidates such as MELT-300, a patented sublingual sedation tablet, and other ophthalmic therapies in development. The company focuses on expanding its commercial infrastructure and sales force to support product launches and growth. Pricing and reimbursement dynamics with government and commercial payors significantly influence its revenue and profitability.
Harrow, Inc. is a North American ophthalmic pharmaceutical company with a broad portfolio of FDA-approved branded products and a significant ophthalmology-focused pharmaceutical compounding business. The company operates two FDA-registered compounding facilities in New Jersey and relies on third-party manufacturers for its branded products. Its development pipeline includes late-stage candidates such as MELT-300, a sublingual sedation therapy that completed Phase 3 trials and is advancing toward FDA approval. Harrow's sales efforts focus primarily on the U.S. market, with some international licensing. Financial figures as of September 30, 2026, include $75.3 million in cash and equivalents, a current ratio of 2.29, and net income of $9.76 million. Recent quarterly earnings reports show challenges with revenue and earnings performance in 2026. Pricing and reimbursement pressures from third-party payors remain a material factor affecting profitability. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Harrow's extensive portfolio of branded ophthalmic products and patented compounded formulations position it well within the ophthalmology market. The MELT-300 program, with completed Phase 3 trials and FDA Special Protocol Assessment, represents a potential transformative non-opioid sedation therapy that could expand beyond ophthalmology into broader procedural sedation markets. Recent product launches and pipeline advancements support potential commercial growth. The company's strong liquidity and expanding sales infrastructure provide a foundation for scaling operations and capturing market opportunities.
Harrow faces risks from pricing and reimbursement pressures that could adversely affect revenue and profitability. The company has reported losses and revenue misses in recent quarters, indicating operational challenges. Licensing restrictions, such as those related to the VEVYE product and the acquisition of TYRVAYA, pose potential legal and commercial uncertainties. Dependence on third-party manufacturers and regulatory approvals introduces execution risks. Competition from larger pharmaceutical and biosimilar companies may limit market share and pricing power.
Harrow's moat derives from its comprehensive portfolio of FDA-approved ophthalmic products combined with a large, patented ophthalmology-focused pharmaceutical compounding business serving over 10,000 U.S. eyecare prescribers. Its proprietary formulations, patent protections on key products and pipeline candidates, and established commercial infrastructure provide competitive advantages. The company's strategic acquisitions, such as Melt Pharmaceuticals, and licensing arrangements further strengthen its product offerings and market position. However, competition from larger pharmaceutical companies and biosimilar manufacturers remains significant, and regulatory and reimbursement challenges persist.
• Pricing and Reimbursement Pressure: Sales depend heavily on coverage and reimbursement from government and commercial payors, with ongoing pressures from utilization management, formulary restrictions, and pricing regulations that could reduce revenues and profitability [Q1-Q4].
• Licensing Restrictions and Legal Uncertainty: License agreements, such as for VEVYE, impose commercialization restrictions that may require divestiture or termination of rights if conflicting products are acquired, as seen with the TYRVAYA acquisition, creating potential operational and financial risks [Q1].
• Regulatory and Clinical Development Risks: Advancement of pipeline products like MELT-300 depends on successful completion of regulatory submissions and approvals, with inherent uncertainties in clinical and regulatory processes [S1].
• Competitive Landscape: The ophthalmic pharmaceutical market is highly competitive with larger companies possessing greater resources, which may challenge Harrow's market penetration and pricing strategies [S1].
• Manufacturing and Supply Chain Dependence: Harrow relies on third-party manufacturers for branded products and operates compounding facilities subject to regulatory oversight, exposing it to supply chain and compliance risks [S1].
Business trends: Expansion of ophthalmic product portfolio with new launches and late-stage pipeline candidates; ongoing pricing and reimbursement challenges impacting profitability.
Execution milestones: Advancement of MELT-300 toward FDA approval and commercialization; integration of acquisitions such as TYRVAYA; scaling of sales and marketing infrastructure.
Key risks: Regulatory and licensing uncertainties, pricing and reimbursement pressures, competitive market dynamics, and supply chain dependencies.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America focused on delivering safe, effective, accessible, and affordable medications to improve patient compliance and clinical outcomes [S1].
- The company markets a comprehensive portfolio of FDA-approved ophthalmic products addressing conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [S1].
- Key branded products include IHEEZO (ocular surface anesthesia gel), VEVYE (cyclosporine ophthalmic solution for dry eye disease), TRIESENCE (steroid injection for ophthalmic diseases), BYOOVIZ (ranibizumab-nuna biosimilar for wet AMD and related conditions), OPUVIZ (aflibercept biosimilar), BYQLOVI (ophthalmic corticosteroid), VIGAMOX (antibiotic eye drop), ILEVRO (NSAID eye drop), FLAREX (corticosteroid suspension), NATACYN (antifungal suspension), TOBRADEX ST (antibiotic and corticosteroid combination), ZERVIATE (histamine-1 receptor antagonist), VERKAZIA (calcineurin inhibitor for vernal keratoconjunctivitis), NEVANAC (NSAID), FRESHKOTE (lubricant eye drop), MAXITROL, MAXIDEX, and IOPIDINE [S1].
- The company owns U.S. commercial rights to these products and has out-licensed Canadian rights for some products to Apotex Inc. [S1].
- Harrow operates two compounding facilities in New Jersey (one FDA-registered 503B outsourcing facility and one licensed 503A pharmacy) producing over 30 patented or patent-pending compounded ophthalmic formulations for more than 10,000 U.S. eyecare prescribers and institutions [S1].
- The company does not manufacture its branded products but relies on third-party manufacturers located in various countries including the U.S., France, Belgium, Spain, Taiwan, and others, with some production transitions planned by end of 2026 [S1].
- Harrow's development pipeline focuses on late-stage and near-commercial ophthalmic and adjacent therapies, including MELT-300 (a patented sublingual midazolam and ketamine tablet for sedation), H-N08 (triamcinolone acetonide ophthalmic program), CR-01 (conjunctival delivery device for ocular neoplasia), and MELT-210 (midazolam ODT) [S1].
- MELT-300 completed Phase 3 clinical trials with FDA Special Protocol Assessment and is advancing toward NDA submission with ongoing non-clinical and pharmacokinetic studies [S1].
- The company acquired the remaining equity interests of Melt Pharmaceuticals in November 2025, consolidating MELT-300 and related R&D activities [S1].
- Sales and marketing efforts are primarily U.S.-focused, targeting eyecare professionals, ambulatory surgery centers, healthcare systems, and hospitals, with some international distribution and licensing [S1].
- Harrow's sales depend on coverage and reimbursement from government and commercial third-party payors, with ongoing pricing and reimbursement pressures affecting profitability [Q1-Q4].
- The company completed acquisition of TYRVAYA nasal spray for dry eye disease in October 2026, with ongoing discussions regarding licensing restrictions related to VEVYE [Q1].
- Financial snapshot as of September 30, 2026: cash and equivalents $75.3 million, current assets $261.3 million, current liabilities $114.2 million, current ratio 2.29, cash ratio 0.72, net income $9.76 million, basic EPS $0.26, diluted EPS $0.25 [S2].
- Recent quarterly earnings reports indicate losses and revenue misses in Q1 and Q2 2026, with Q3 earnings lagging estimates [N1][N2][N4][N5][N6][N8].
- The company has recently launched or plans to launch several products including BYOOVIZ and BYQLOVI in mid-2026 and OPUVIZ in mid-2027 [S1].
- Harrow's MELT-300 program aims to provide a non-opioid, non-IV sublingual sedation therapy for procedural sedation, potentially expanding beyond ophthalmology into other outpatient procedures [S1].
Generated 2026-11-10
- S1 | 2026-03-02 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-09 | www.nasdaq.com | Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say | https://www.nasdaq.com/articles/harrow-hrow-reports-q3-earnings-what-key-metrics-have-say
- N2 | 2026-11-09 | www.nasdaq.com | Harrow (HROW) Q3 Earnings Lag Estimates | https://www.nasdaq.com/articles/harrow-hrow-q3-earnings-lag-estimates
- N3 | 2026-11-06 | www.nasdaq.com | Profound Medical (PROF) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/profound-medical-prof-reports-q3-loss-beats-revenue-estimates
- N4 | 2026-08-17 | www.nasdaq.com | Harrow (HROW) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/harrow-hrow-q2-2026-earnings-call-transcript
- N5 | 2026-08-11 | www.nasdaq.com | Harrow Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/harrow-q2-earnings-call-highlights
- N6 | 2026-08-11 | www.nasdaq.com | Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/harrow-hrow-reports-q2-loss-misses-revenue-estimates
- N7 | 2026-08-06 | www.nasdaq.com | Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates | https://www.nasdaq.com/articles/ironwood-pharmaceuticals-irwd-q2-earnings-top-estimates
- N8 | 2026-05-12 | www.nasdaq.com | Harrow (HROW) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/harrow-hrow-q1-2026-earnings-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


